Overview
An extended version of Argireline built on the premise that a longer SNAP-25 mimic competes more effectively in the SNARE complex. The mechanism is coherent; the evidence is thinner than for its predecessor and comes mainly from the supplier.
Cosmetic IngredientCosmetic ingredient. Manufacturer studies claim superiority over Argireline; independent replication is limited.
| Regulatory status | Cosmetic ingredient. Manufacturer studies claim superiority over Argireline; independent replication is limited. |
|---|---|
| Drug class | Synthetic octapeptide — an elongated analog of Argireline |
| Route | Topical |
| Half-life | Not applicable — topical |
| Evidence rating |
2/5 Limited
Evidence rating 2 out of 5: Limited
Preclinical work plus scattered human reports, uncontrolled use, or negative trials. |
| Studied in | Manufacturer-sponsored topical studies reporting wrinkle-depth reduction; limited independent published work. |
How it works
An eight-residue extension of the acetyl hexapeptide sequence, designed for stronger competitive inhibition of SNAP-25 within the SNARE complex, reducing neurotransmitter vesicle docking and muscle contraction intensity.
Evidence base
Rated 2 of 5 — Limited. Preclinical work plus scattered human reports, uncontrolled use, or negative trials.
- Plausible mechanism, limited independent evidence.
Benefits & potential uses
Bars indicate how well each claim is supported: three = strong human evidence, two = moderate, one = preliminary or preclinical.
-
Reported wrinkle-depth reduction Preliminary
Supplier studies report reductions of roughly 30% over 4 weeks, exceeding Argireline in the same protocols.
-
Good tolerability Moderate evidence
Topical use is well tolerated with minimal irritation reported.
-
Non-invasive alternative Moderate evidence
No injections; usable at home.
Risks, cons & cautions
Bars indicate seriousness: three = serious or common, two = moderate, one = minor.
-
Evidence base is largely manufacturer-generated Moderate evidence
Independent peer-reviewed replication is limited.
-
Penetration challenges Moderate evidence
A larger peptide faces a harder time crossing the stratum corneum than the hexapeptide it extends.
-
Effects reverse on discontinuation Minor
Requires continued use.
-
Marketing outpaces data Moderate evidence
"Better than Argireline" claims rest on a narrow evidence base.
Who should avoid it
- Known ingredient allergy
- Irritated or broken skin
If used under medical supervision, monitor
- None required
Regulatory & legal status
Lawful cosmetic ingredient.
Infographic
Where to read further
We link to live literature searches rather than a frozen citation list, so you always see current results — including anything published after our last review.
- PubMed — all published literature on SNAP-8 (Acetyl Octapeptide-3)
- PubMed — randomized controlled trials only
- ClinicalTrials.gov — registered human trials
Related peptides in Skin & Cosmetic
Terms used on this page
- Stratum Corneum
- The stratum corneum is the outermost epidermal layer of dead, keratin-filled corneocytes in a lipid matrix, and it is the rate-limiting barrier for essentially every topical ingredient.
This page is educational information, not medical advice. It cannot account for your medical history, medications, or risk factors. Do not start, stop or change any treatment based on it. Speak to a qualified healthcare professional who knows your case.